Details:
Under the terms of this agreement, Tabuk Pharmaceuticals will hold the marketing authorisation for select speciality products including Glaricon and be responsible to register, importing, and promoting them in Saudi Arabia and other Middle East countries.
Lead Product(s): Insulin Glargine
Therapeutic Area: Endocrinology Product Name: Glaricon
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Biocon
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 07, 2021